摘要
在肿瘤患者中,程序性细胞死亡受体-1(Programmed cell death-1,PD-1)可通过与其配体(ligand,L)的结合抑制T细胞活化与增殖,从而促进肿瘤免疫逃逸。大量实验显示,PD-L1在淋巴瘤中高表达,而PD-1在肿瘤浸润淋巴细胞表达上调,提示其在淋巴瘤发生中的作用,可能为淋巴瘤重要治疗靶点。PD-1及PD-L1的单克隆抗体可阻断PD-1/PD-Ls信号通路,恢复T细胞功能,对肿瘤起抑制作用。目前多项应用PD-1抗体的早期临床试验已经在复发淋巴瘤的各种亚型中显示出显著的疗效及较少毒副作用,为目前有前途的靶向治疗药物。本文就PD-1/PD-L1信号通路作用机制、PD-1/PD-L1在淋巴瘤中的表达以及其抗体在淋巴瘤中的抗肿瘤作用作一综述。
In tumor patients,programmed cell death-1（ PD-1） can inhibit T-cell activation and proliferation by binding to its ligand,thereby promote tumor immune escape.A large number of experiments showed that PD-L1 molecule highly expressed on lymphoma cells,while PD-1 expression was up-regulated in tumor-infiltrating lymphocytes,suggesting its role in the development of lymphoma,which may be an important therapeutic target for lymphoma.PD-1 and PD-L1 monoclonal antibodies can block the PD-1/PD-Ls signaling pathway,restore T cell function,thus inhibit the tumor growth.At present,a number of early clinical trials have demonstrated the significant efficacy and less side effects in various subtypes of recurrent lymphoma,which will be promising therapeutic agents.In this review,the mechanism of PD-1/PD-L1 signal pathway,the expression of PD-1/PD-L1 in lymphoma and the anti-tumor effect of its antibody in lymphoma are summarized.
作者
李文静
王晶
克晓燕
LI Wen-Jing;WANG Jing;KE Xiao- Yan(Department of Hematology, Peking University Third Hospital, Beijing 100191, China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2018年第3期922-927,共6页
Journal of Experimental Hematology
基金
博士点基金(博导类)(20130001110090)
PDL1及Tregs在淋巴瘤肿瘤免疫逃避中的作用及机制研究
国家自然科学基金(81470358)CMTM1-v5特异性杀伤淋巴瘤细胞的机制研究
